Skip to main content
Evidence Snapshot

Coagulation factor VII

CHEMBL3991 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3991
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor VII as ChEMBL target CHEMBL3991, mapped to UniProt P08709. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor VII
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3991
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08709
Coagulation factor VII
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Coagulation factor VII matters

As of 2026-09-13

Coagulation factor VII is reviewed as Coagulation factor VII (UniProt P08709); Coagulation factor VII shows approved-linked disease relevance led by hemophilia A. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 792 compounds, and 182 assays, with lead potency reaching pChEMBL 10.7.

Disease context
hemophilia A

Coagulation factor VII shows approved-linked disease relevance led by hemophilia A. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include EPTACOG ALFA (ACTIVATED), EPTACOG ALFA PEGOL (ACTIVATED), EPTACOG BETA (ACTIVATED).

Start review with hemophilia A because it currently carries approved-linked support. Linked drugs include EPTACOG ALFA (ACTIVATED), EPTACOG ALFA PEGOL (ACTIVATED), EPTACOG BETA (ACTIVATED). This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 792 compounds, and 182 assays for this target. The dominant activity type is KI. CHEMBL3930738 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL3930738 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Coagulation factor VII matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08709, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hemophilia A is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

792
Total Compounds
182
Total Assays
1
Approved Drugs
IC50: 265.0, KI: 486.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3930738
 10.7 Ki —
No preferred name
CHEMBL3986081
 10.3 Ki —
No preferred name
CHEMBL3902759
 9.9 Ki —
No preferred name
CHEMBL3977297
 9.8 Ki —
No preferred name
CHEMBL3969432
 9.8 Ki —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3991